Log in
Naughty or nice: a look at the month’s biggest IP wins and losses
From copyrights to trademarks to patents: a roundup of this month's news and trends from the world of Intellectual Property.
"Don’t copy that IP!" Pirated and counterfeit software
Understanding how pirated and counterfeit software differ is critical to knowing the best ways to protect the underlying IP.
Taking products at face value: trademarks and origin
A roundup of the biggest Intellectual Property (IP) stories from around the world.
IP Valuation: How to measure what you cannot see
In some cases, the worth of an organization's IP far exceeds that of its physical resources, property or other holdings.
Push vs. pull: patents and access to medicines
The COVID-19 pandemic has brought the issue of access to affordable medicines to the forefront of Intellectual Property (IP) debate in recent months.
Defensive publication or patent application: Which works best?
Choosing a defensive publication over the traditional patent application route makes sense under certain circumstances.
A chocolate bunny meltdown and other IP bites
A roundup of the biggest Intellectual Property (IP) stories from around the world.
Everyday IP: The technology behind movie magic
Several critical phases of innovation, each involving one or more inventors, ensured that moviemaking evolved from a curiosity into mainstream entertainment.
What happens now to Royal Warrants of Appointment?
For many businesses, large and small, succession brings not only a change in ruler but a change in their marketing.
Sustainability in the Intellectual Property life cycle
Unleash the power of IP and innovation to realize business success.
Everyday IP: Mickey Mouse and the tale of Intellectual Property in film
The issue of Disney's signature Mickey Mouse character entering the public domain is just one example of IP's major — and multifaceted — effects on the movie business.
Moderna sues Pfizer / BioNTech for COVID vaccine patent infringement
Though Intellectual Property (IP) disputes are not uncommon in the pharmaceutical industry, the scale and prominence of this litigation are of rare magnitude.